[go: up one dir, main page]

WO2021050564A3 - Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders - Google Patents

Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders Download PDF

Info

Publication number
WO2021050564A3
WO2021050564A3 PCT/US2020/049965 US2020049965W WO2021050564A3 WO 2021050564 A3 WO2021050564 A3 WO 2021050564A3 US 2020049965 W US2020049965 W US 2020049965W WO 2021050564 A3 WO2021050564 A3 WO 2021050564A3
Authority
WO
WIPO (PCT)
Prior art keywords
lyme disease
methods
therapeutic agents
related disorders
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/049965
Other languages
French (fr)
Other versions
WO2021050564A2 (en
Inventor
Jayakumar Rajadas
Hari Hara SURYA KUMAR POTULA
Mohammed INAYATHULLAH NAZIR AHMED
Venkata Raveendra Pothineni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2021050564A2 publication Critical patent/WO2021050564A2/en
Publication of WO2021050564A3 publication Critical patent/WO2021050564A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are methods of reducing inflammation in subjects having Borrelia infections and related disorders, the methods including administering therapeutic agents to the subjects and measuring inflammatory and immune markers.
PCT/US2020/049965 2019-09-11 2020-09-09 Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders Ceased WO2021050564A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962899134P 2019-09-11 2019-09-11
US62/899,134 2019-09-11
US201962923519P 2019-10-19 2019-10-19
US62/923,519 2019-10-19
US202062983467P 2020-02-28 2020-02-28
US62/983,467 2020-02-28

Publications (2)

Publication Number Publication Date
WO2021050564A2 WO2021050564A2 (en) 2021-03-18
WO2021050564A3 true WO2021050564A3 (en) 2021-04-22

Family

ID=74870039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/049965 Ceased WO2021050564A2 (en) 2019-09-11 2020-09-09 Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders

Country Status (1)

Country Link
WO (1) WO2021050564A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115308313A (en) * 2021-05-08 2022-11-08 成都倍特药业股份有限公司 Method for detecting acetaldehyde in potassium clavulanate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017124080A1 (en) * 2016-01-17 2017-07-20 Jayakumar Rajadas Methods and drug compositions for treating lyme disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017124080A1 (en) * 2016-01-17 2017-07-20 Jayakumar Rajadas Methods and drug compositions for treating lyme disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CALLISTER ET AL.: "Detection of IFN-gamma Secretion by T Cells Collected Before and After Successful Treatment of Early Lyme Disease", CLIN INFECT DIS., vol. 62, no. 10, 15 May 2016 (2016-05-15), pages 1235 - 1241, XP008182255, DOI: 10.1093/cid/ciw112 *

Also Published As

Publication number Publication date
WO2021050564A2 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2025008493A (en) Fibroblast binding agents and use thereof
MX2021002321A (en) Novel methods.
PH12017501323A1 (en) Use of prg4 as an anti-inflammatory agent
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
PH12023552763A1 (en) Agonistic anti-il-2r antibodies and methods of use
MY171929A (en) Corticosteroids for the treatment of joint pain
BR112016020381A8 (en) drug release systems and methods for treating gemcitabine bladder cancer.
PH12020551905A1 (en) C-mannoside compounds useful for the treatment of urinary tract infections
BR112015010039A2 (en) treatment of cancer with pomalidomide in an individual with renal dysfunction
SA519410993B1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2021003681A (en) Benzimidazole derivative for use in the treatment of inflammatory disorders.
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2021050564A3 (en) Therapeutic agents and methods for treatment of lyme disease and lyme disease-related disorders
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
WO2023019095A3 (en) Momelotinib combination therapy
WO2019014322A8 (en) Kinase inhibitors for treatment of disease
MX2023005663A (en) RESPIRATORY TREATMENTS.
BR112022010458A2 (en) PEDIATRIC FORMULATION FOR IMMEDIATE RELEASE OF EZOGABINE POTASSIUM CHANNEL OPENER
SA520420147B1 (en) Triazacyclododecansulfonamide (“TCD”)-Based Protein Secretion Inhibitors
MX2021007324A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20862116

Country of ref document: EP

Kind code of ref document: A2